Loading clinical trials...
Loading clinical trials...
The purpose of this trial is to evaluate if it is safe to use tissue plasminogen activator (tPA) within 6 hours of stroke onset when combined with hypothermia.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of California, San Diego
Collaborators
NCT05600374 · Ischemic Stroke, Acute
NCT07575867 · Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, and more
NCT04875936 · Stroke, Dyslexia, Acquired
NCT07084025 · Stroke, Cerebrovascular Disorders
NCT06292117 · Ischemic Stroke, CYP2C19 Polymorphism
Stanford Medical Center
Palo Alto, California
University of California San Diego, Thornton Hospital
San Diego, California
Scripps Mercy Hospital
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions